USFDA concludes inspection at Zydus’ LiqMeds in U.K. with four observations

The US Food and Drug Administration has concluded an inspection of Zydus Lifesciences' LiqMeds facility in the U.K., issuing four observations. The company has committed to working with regulators to address these findings promptly.
Why it matters
Regulatory observations from the USFDA can impact a pharmaceutical company's operational compliance and market access, often influencing investor confidence.
New Delhi Zydus Lifesciences on Saturday (November 14, 2026) said the U.S. health regulator has concluded its inspection at LiqMeds, U.K., with four observations. The inspection was conducted from November 9-13, the company said in a regulatory filing to stock exchanges. "The company will closely work with the U.S.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in